PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING GLIOBLASTOMA CONTAINING GEMCITABINE-CAPTURED IMMUNE LIPOSOME AND BEVACIZUMAB AS ACTIVE INGREDIENTS

摘要

The present invention relates to a pharmaceutical composition for preventing or treating glioblastoma, which is bound to an anti-CD133 antibody and contains liposome (133-L-GEM), including captured gemcitabine and being PEGylated, and bevacizumab as active ingredients. More specifically, the pharmaceutical composition of the present invention exhibits a significant growth inhibition effect specific to glioblastoma stem cells due to binding of the anti-CD133 antibody. The pharmaceutical composition of the present invention reduces an injection amount of BV since the pharmaceutical composition inhibits VEGF secreted from GSC, and thus inhibits GSC-derived new blood vessels. A combined treatment of the immune liposome and bevacizumab exhibits a significant synergy effect on the treatment of glioblastoma compared to a single treatment. Therefore, the pharmaceutical composition of the present invention can be advantageously used as a composition for preventing and treating glioblastoma, or inhibiting transition of glioblastoma.;COPYRIGHT KIPO 2017